VNDA · Vanda Pharmaceuticals Inc
United States · RS rating 17 · As of 2026-11-03
| Price | 3.75 USD |
|---|---|
| 1-day change | -3.4% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 23 / 24 / 41 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 18 / 6 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -529.0% |
| Sales growth Q/Q | +1.7% |
| Distance from 52-week high | +60.8% |
| Market cap (USD) | $395.4M |